Exploring the Epigenetic Regulation of Immune Cells in Chronic Inflammation

Sofia Aguilar^*
*Correspondence: Sofia Aguilar, Department of Cellular and Molecular Biology, National Autonomous University of Mexico, Coyoacán, Mexico City, Mexico, Email:

Introduction

Chronic inflammation is a persistent and dysregulated immune response that underlies various diseases, including rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, and cancer. While genetic predispositions play a critical role in influencing an individual's susceptibility to these conditions, the contribution of epigenetic regulation has emerged as a pivotal factor in understanding the mechanisms of chronic inflammation. Epigenetic changes, modifications to gene expression that do not involve alterations in the DNA sequence, allow immune cells to dynamically respond to environmental and pathological stimuli. Key epigenetic mechanisms, such as DNA methylation, histone modifications, and non-coding RNAs, regulate immune cell activation, differentiation, and function. This article delves into the role of epigenetic regulation in chronic inflammation, highlighting how it influences the behavior of key immune cells, including macrophages, T cells, and B cells. By elucidating these mechanisms, we can uncover potential therapeutic targets for modulating chronic inflammation and improving the management of inflammation-associated diseases [1].

Description

Epigenetic mechanisms in immune cells

Epigenetic modifications enable immune cells to respond adaptively to environmental cues, influencing both the resolution and perpetuation of inflammation. One of the most studied mechanisms is DNA methylation, where the addition of methyl groups to cytosine residues in DNA represses gene expression. For instance, in chronic inflammatory states, hypermethylation of anti-inflammatory genes or hypomethylation of pro-inflammatory genes can skew immune responses toward prolonged inflammation. Histone modifications, including acetylation, methylation, and phosphorylation, further regulate chromatin structure and gene accessibility. Acetylation of histones generally promotes gene expression by loosening chromatin, while methylation can either activate or repress genes depending on the specific histone residue modified. In macrophages, histone modifications are critical for controlling the expression of inflammatory cytokines such as IL-1β and TNF-α. Dysregulated histone acetylation or methylation can lock macrophages into a proinflammatory state, contributing to chronic tissue damage. Non-coding RNAs, particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), also play a crucial role in the epigenetic regulation of immune cells. These RNAs modulate the expression of inflammatory genes post-transcriptionally, either by degrading mRNA or inhibiting translation. Dysregulated miRNAs, such as miR- 146a and miR-155, have been implicated in chronic inflammatory conditions, as they disrupt the balance between pro- and anti-inflammatory signals in immune cells [2,3].

Epigenetic regulation in T cells and B cells

Epigenetic mechanisms are central to the differentiation and function of T cells, including effector T cells, regulatory T cells (Tregs), and memory T cells. DNA methylation patterns and histone modifications determine the differentiation of naive T cells into specific subsets, such as pro-inflammatory Th1 and Th17 cells or anti-inflammatory Tregs. For example, demethylation of the FOXP3 gene promoter is essential for Treg differentiation and function. Dysregulation in these epigenetic processes can lead to an imbalance between pro-inflammatory and regulatory responses, exacerbating chronic inflammation. In B cells, epigenetic regulation influences antibody production and class switching, processes critical for adaptive immunity. Abnormal epigenetic patterns in B cells, such as altered DNA methylation in immunoglobulin genes, have been linked to autoantibody production in autoimmune diseases like Systemic Lupus Erythematosus (SLE). These epigenetic changes disrupt normal immune tolerance, leading to the sustained activation of B cells and chronic inflammation [4].

Therapeutic implications

Targeting epigenetic modifications offers a promising strategy for managing chronic inflammation. Epigenetic drugs, such as DNA methyltransferase inhibitors (e.g., azacytidine) and histone deacetylase inhibitors (e.g., vorinostat), have shown potential in modulating inflammatory responses. These agents can restore normal epigenetic patterns, reactivating suppressed anti-inflammatory genes or silencing pro-inflammatory genes. Additionally, strategies targeting non-coding RNAs are being explored for therapeutic purposes. Synthetic miRNA mimics or inhibitors (antagomirs) can modulate the expression of specific inflammatory genes. For example, targeting miR-155 has been shown to reduce inflammation in preclinical models of rheumatoid arthritis. Combining epigenetic therapies with existing anti-inflammatory drugs could enhance treatment efficacy and provide more durable remission in patients with chronic inflammatory diseases [5].

Conclusion

Epigenetic regulation plays a pivotal role in shaping immune cell behavior in chronic inflammation, offering new insights into the pathogenesis of inflammatory diseases. By modulating gene expression without altering the DNA sequence, epigenetic mechanisms provide immune cells with the plasticity needed to respond to dynamic environmental and pathological signals. However, when dysregulated, these mechanisms contribute to the persistence of inflammation and the development of chronic disease. Advances in epigenetic research have uncovered promising therapeutic targets, paving the way for innovative treatments that restore immune balance. By targeting specific epigenetic modifications or pathways, it is possible to modulate immune cell activity, reduce inflammation, and improve disease outcomes. As we continue to deepen our understanding of the epigenetic landscape in immune cells, the potential for personalized epigenetic therapies to transform the management of chronic inflammation becomes increasingly clear. Such therapies hold the promise of not only alleviating symptoms but also addressing the root causes of inflammation, ultimately improving the quality of life for patients worldwide.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Caldwell, Blake A. and Liwu Li. "Epigenetic regulation of innate immune dynamics during inflammation." J Leukoc Biol 115 (2024): 589-606.

Google Scholar, Crossref, Indexed at

2. Busslinger, Meinrad and Alexander Tarakhovsky. "Epigenetic control of immunity." Cold Spring Harb Perspect Biol 6 (2014): a019307.

Google Scholar, Crossref, Indexed at

3. Britt, Emily C., Steven V. John, Jason W. Locasale and Jing Fan. "Metabolic regulation of epigenetic remodeling in immune cells." Curr Opin Biotechnol 63 (2020): 111-117.

Google Scholar, Crossref, Indexed at

4. Frias, Adolfo B., Shannon K. Boi, Xin Lan and Ben Youngblood. "Epigenetic regulation of T cell adaptive immunity." Immunol Rev 300 (2021): 9-21.

Google Scholar, Crossref, Indexed at

5. Guo, Lei, Yi-Tsang Lee, Yubin Zhou and Yun Huang. "Targeting epigenetic regulatory machinery to overcome cancer therapy resistance." Semin Cancer Biol 83 (2022): 487-502.

Google Scholar, Crossref, Indexed at